Data Bridge Market Research analyses that the diabetic retinopathy market was valued at USD 6.60 billion in 2021 and is expected to reach USD 12.68 billion by 2029, registering a CAGR of 8.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framewor

In recent years, the diabetic retinopathy market is anticipated to grow rapidly during the forecast period. Diabetic retinopathy (DR) is the most common cause of visual loss worldwide. The duration of hyperglycemia, diabetes and hypertension are the most clinically important risk factors for vision loss progression. Controlling blood sugar and blood pressure has been demonstrated to help prevent vision loss due to diabetic retinopathy. According to the International Diabetes Federation (IDF), the global prevalence of diabetes mellitus (DM) was around 27% from 2015 to 2019. The lowest rates were found in Europe (20.6%) and Southeast Asia (12.5%), while the most significant rates were found in Africa (33.8%), the Middle East and North Africa (33.8%), and the Western Pacific region (36.2%).

Access Full Report: https://www.databridgemarketresearch.com/reports/global-diabetic-re...

Diabetes mellitus damages the blood vessels in the retina, resulting in diabetic retinopathy (DR). There are two types of diabetic retinopathy: non-proliferative and proliferative or progressed diabetic retinopathy. It is caused by changes in blood glucose levels, which cause abnormal growth of the light-sensitive structures in the eye. Dark patches or floating strings in the vision field, hazy or fluctuating vision, decreased colour vision, or vision loss are all symptoms of diabetic retinopathy.

Recent Development

In August 2020, Eyenuk had announced the U.S. Food and Drug Administration (FDA) approval for EyeArt Autonomous AI System for diabetic retinopathy screening. EyeArt is designed to help healthcare providers detect more than moderate diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR) in the eyes of adults with diabetes who have never been diagnosed with more than mild diabetic retinopathy.
Global Diabetic Retinopathy Market Scope
The diabetic retinopathy market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

Non-Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Type segment for the diabetic retinopathy market is categorized into non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.

Treatment

Medication
Device
Surgery
Others
Based on treatment, the diabetic retinopathy market is segmented into medication, device, surgery and others. The medication section is further categorized into anti-vascular endothelial growth factor drug, intravitreal steroid, lipid lowering drugs and others. The device section has been sub-segmented into focal laser, vitrectomy devices, scatter laser and others.

Diagnosis

Fluorescein Angiography
Optical Coherence Tomography
Others
Based on diagnosis, the diabetic retinopathy market is segmented into fluorescein angiography, optical coherence tomography and others.

Route of Administration

Oral
Intravitreal Injections
Intravitreal Implants
Others
The route of administration segment for global diabetic retinopathy market is segmented into oral, intravitreal injections, intravitreal implants and others.

End-Users

Hospitals
Specialty Clinics
Homecare
Others
On the basis of end-users, the diabetic retinopathy market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
On the basis of distribution channel, the diabetic retinopathy market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Diabetic Retinopathy Market Regional Analysis/Insights
The diabetic retinopathy market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Diabetic retinopathy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the diabetic retinopathy market because of the growing prevalence of diabetic retinopathy and the presence of refined healthcare expenditure in this region. Additionally, growing focus of major key players on novel technology will further propel the 'market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 due to the population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Diabetic Retinopathy Market Share Analysis
The Diabetic retinopathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to diabetic retinopathy market.

Some of the major players operating in the diabetic retinopathy market are:

LEO Pharma A/S (Denmark)
Amneal Pharmaceuticals LLC. (US)
Glenmark Pharmaceuticals Limited (India)
Dr. 'Reddy's Laboratories Ltd. (India)
AstraZeneca (UK)
Johnson & Johnson Private Limited (US)
Bausch Health Companies Inc. (Canada)
Eli Lilly and Company (US)
AbbVie Inc. (US)
Abbott (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (US)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
Novartis AG (Switzerland)
Sun Pharmaceutical Industries Ltd. (India)
Aurobindo Pharma (India)
Lupin (India)
Allergan (Ireland)
Merck & Co., Inc. (US)
IRIDEX Corporation (US)
Pfizer Inc. (US)
GlaxoSmithKline plc (UK)